{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046069","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.151265+00:00","generated_at":"2026-05-24T04:14:46.866134+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SeaStar Medical reports FY2024 net loss $24.8M; first product revenue $0.1M from QUELIMMUNE launch","bullets":["Net loss for 2024 was $24.8M ($6.63 per share) vs $26.2M ($30.26) in 2023.","First net revenue of $0.1M from QUELIMMUNE pediatric AKI therapy approved via HDE in Q1 2024.","NEUTRALIZE AKI pivotal trial enrolled 94 of 200 patients; added 14 sites in 2024.","Raised ~$31M in capital and reduced debt; $6M registered direct financing completed Feb 2025.","Cash and short-term investments $1.8M at Dec 31, 2024, before February financing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046069","json":"https://secwatch.observer/filing/0000950170-25-046069.json","markdown":"https://secwatch.observer/filing/0000950170-25-046069.md","text":"https://secwatch.observer/filing/0000950170-25-046069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000095017025046069/0000950170-25-046069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000095017025046069/icu-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:14:46.866134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}